特发性肺纤维化的肺移植
本文综述特发性肺纤维化(IPF)肺移植的现状与挑战,强调对胃食管反流、肺动脉高压、冠心病和恶性肿瘤等合并症采取主动管理策略;讨论供体短缺与等待名单死亡率高背景下的器官分配系统,以及抗纤维化治疗、体外生命支持技术、遗传学理解和多学科整体照护的进展。
要点
- 肺移植是唯一被证实能延长IPF患者预期寿命的干预措施。
- 需主动管理IPF合并症:胃食管反流、肺动脉高压、冠心病和恶性肿瘤。
- 供体池不足与等待名单死亡率高是肺移植的主要挑战。
核心结论
- 肺移植是唯一被证实能延长IPF患者预期寿命的干预措施,但伴随疾病特异性挑战。
研究设计与样本
- 本文为综述,讨论IPF肺移植的合并症管理、器官分配系统及多领域进展。
主要发现
- 供体池不足以满足需求,且移植等待名单死亡率高。
- 抗纤维化治疗、体外生命支持技术进步、疾病遗传学理解及多学科整体照护正在快速发展。
临床怎么用
- 对IPF患者应采取主动策略管理胃食管反流、肺动脉高压、冠心病和恶性肿瘤等合并症。
- 关注国际上不同器官分配系统以促进供体分配。
- 采用多学科整体照护方法管理IPF肺移植患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis. Lung transplantation is the only intervention shown to increase life expectancy for patients with IPF, but it is associated with disease-specific challenges. In this Review, we discuss the importance of a proactive approach to the management of IPF comorbidities, including gastro-oesophageal reflux, pulmonary hypertension, coronary artery disease, and malignancy. With a donor pool too small to meet demand and unacceptably high mortality on transplant waiting lists, we discuss different systems used internationally to facilitate organ allocation. We explore the rapidly evolving landscape of transplantation for patients with IPF with regards to antifibrotic therapy, technological advances in extracorporeal life support, advances in understanding of the genetics of the disease, and the importance of a holistic multidisciplinary approach to care. Finally, we consider potential advances over the next decade that are envisaged to improve transplantation outcomes in patients with advanced IPF.
引用
- George PM, Patterson CM, Reed AK, et al. Lung transplantation for idiopathic pulmonary fibrosis. Lancet Respir Med. 2019. PMID: 30738856. doi:10.1016/S2213-2600(18)30502-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。